What is the significance of Samsung Biologics' $1.8 billion acquisition of PolyPeptide Group?

The $1.8 billion all-cash bid for PolyPeptide Group is the largest ever made by a South Korean biopharmaceutical company, marking Samsung Biologics’ strategic expansion from its current focus on monoclonal antibodies, antibody-drug conjugates, and other large-molecule therapeutics into the fast-growing peptide market.

Why is Samsung Biologics entering the peptide manufacturing space now?

Samsung Biologics is entering the peptide manufacturing space to gain new capability and expertise in peptides—a modality surging in demand due to the popularity of glucagon-like peptide-1 (GLP-1) drugs for weight loss, and with growing exploration in oncology and other disease areas.

Samsung Makes $1.8 Billion Bet on Peptide Production

Jul 22, 2026

Samsung Biologics launched a $1.8 billion bid for Swiss peptide maker PolyPeptide Group, expanding its contract manufacturing business into the fast-growing peptide market driven by GLP-1 drugs.

cen

2026-07-22

Samsung Makes $1.8 Billion Bet on Peptide Production

2026-09-01

Samsung Biologics launches $2B rights offering to fund expansion

Samsung Makes $1.8 Billion Bet on Peptide Production

FAQ